Key Information
Source
Year
2024
summary/abstract
Brief Summary
The purpose of this study is to characterize cardiac safety of Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone (D-VCd) treatment regimens (Arm A: daratumumab + immediate VCd treatment and Arm B: daratumumab + deferred VCd) in newly diagnosed systemic amyloid light chain (AL) amyloidosis with cardiac involvement and to identify potential mitigation strategies for cardiac toxicity (cohort 1); to characterize the pharmacokinetics of subcutaneous (SC) daratumumab, among racial and ethnic minorities, including Black or African American, with newly diagnosed AL amyloidosis treated with D-VCd (cohort 2).
Show lessexternal link, opens in a new tab
Official Title
(AL) Amyloidosis
Conditions
Amyloidosis
Amyloidosis
Intervention / Treatment
Drug Drug : DaratumumabDrug Drug : CyclophosphamideDrug Drug : BortezomibDrug Drug : Dexamethasone
Other Study ID Numbers
- CR109160
- 2021-002639-48 ( EudraCT Number )
- 54767414AMY2009 ( Other Identifier ) (OTHER: Janssen Research & Development, LLC)
- 2023-507069-25-00 ( Registry Identifier ) (REGISTRY: EUCT number)
- CR109160
- 2021-002639-48 ( EudraCT Number )
- 54767414AMY2009 ( Other Identifier ) (OTHER: Janssen Research & Development, LLC)
- 2023-507069-25-00 ( Registry Identifier ) (REGISTRY: EUCT number)
- CR109160
- 2021-002639-48 ( EudraCT Number )
Show 2 more study numbersexternal link, opens in a new tab